Rhenman & Partners Asset Management’s Oscar Health OSCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.57M Buy
660,000
+400,000
+154% +$5.63M 0.93% 45
2025
Q4
$3.74M Buy
+260,000
New +$4.5M 0.35% 72
2025
Q3
Sell
-312,092
Closed -$6.69M 98
2025
Q2
$6.69M Sell
312,092
-710,651
-69% -$10.6M 0.85% 40
2025
Q1
$13.4M Sell
1,022,743
-339,678
-25% -$5.04M 1.54% 26
2024
Q4
$18.3M Sell
1,362,421
-8,726
-0.6% -$140K 1.88% 20
2024
Q3
$29.1M Sell
1,371,147
-535,464
-28% -$9.64M 2.36% 14
2024
Q2
$30.2M Buy
1,906,611
+215,089
+13% +$3.95M 2.9% 8
2024
Q1
$25.2M Buy
1,691,522
+499,468
+42% +$6.84M 2.38% 13
2023
Q4
$10.9M Buy
1,192,054
+422,054
+55% +$2.91M 1.09% 34
2023
Q3
$4.29M Buy
+770,000
New +$5.39M 0.46% 55

Other funds holding OSCR

Rhenman & Partners Asset Management's OSCR Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Oscar Health (OSCR) stake by 154% in Q1 2026, buying an estimated $5.63M and bringing the position to 660,000 shares worth $7.57M. The position accounts for 0.93% of the portfolio, ranked #45.

Rhenman & Partners Asset Management first reported a position in OSCR in Q3 2023 and has held it in 10 quarters since. The position peaked at $30.2M in Q2 2024. 330 funds tracked by Wall St. Rank hold OSCR as of Q1 2026.

  • Rhenman & Partners Asset Management held 660,000 shares of Oscar Health worth $7.57M as of Q1 2026.
  • Rhenman & Partners Asset Management bought 400,000 Oscar Health shares in Q1 2026, an estimated $5.63M.
  • Oscar Health made up 0.93% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #45 holding.
  • Rhenman & Partners Asset Management first reported a position in Oscar Health in Q3 2023 and has held it in 10 quarters since.
  • Rhenman & Partners Asset Management's Oscar Health position peaked at $30.2M in Q2 2024.
  • 330 funds tracked by Wall St. Rank held Oscar Health as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.